A study using albino cane toads with edited genes challenges the belief that albino wildlife is rare because it’s more ...
Ineos is in negotiations with its partner, the Chinese state-owned oil and chemical company Sinopec, to exit their ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment ...
Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...
In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...
A world-first clinical trial has successfully used a one-off CRISPR gene edit to significantly reduce LDL cholesterol and triglycerides in patients with stubborn lipid disorders.
Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback